Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Lexeo's PKP2 gene therapy shows arrhythmia drop as company maps faster regulatory route

Lexeo says early LX2020 results and its reading of FDA's stance could shorten the path to market, though the agency has not confirmed that position.

16 Nov 2026 · Lexeo Therapeutics, Inc. LXEO · Company news

Lexeo Therapeutics is putting a faster regulatory route at the centre of the case for LX2020, its gene therapy for heart disease caused by PKP2 mutations. The company said on 16 November 2026, in an investor presentation, that the US Food and Drug Administration is receptive to using a measure of arrhythmia as the main endpoint for a possible conditional approval. The material available to CompePharma contains no revenue projections, pricing or deal terms, so the commercial implications remain unquantified.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Lexeo Therapeutics, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →